⌘K

08:00:00·1178d

PRReleasevia Quantisnow

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

ByQuantisnow·Wall Street's wire, on your screen.

CRSP· CRISPR Therapeutics AG VRTX· Vertex Pharmaceuticals Incorporated

Health Care

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | Quantisnow